# SARS-CoV-2
Live literature review on our current knowledge about the Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).<br>
This page will be updated as new papers will be published.<br>
The idea is to have a clear, essential, unbiased, rigorous and simple collection of information from verified sources for both the scientific community and the general public.

If you would like to contribute to the project, send improvements or corrections write an email to <simone.monachino@studenti.unitn.it>

Note: The date (yy/mm/dd) specifies when the article was posted and its link redirects to the DOI of the paper.<br>
NPR means "Not Peer Reviewed".

## Basic Reproduction Number (R0)
- ``Range = 3.80 - 8.90`` [20/04/07](https://doi.org/10.3201/eid2607.200282)
- ``Range = 1.40 - 3.90`` [20/03/26](https://doi.org/10.1056/NEJMoa2001316)
- ``Range = 2.24 - 3.58`` [20/03/01](https://doi.org/10.1016/j.ijid.2020.01.050)
- ``Range = 2.47 – 2.86`` [20/02/29](https://doi.org/10.1016/S0140-6736(20)30260-9)

## Incubation Period
- ``Range = 2.0 - 7.00 days. Median = 4 days (n = 291)`` [20/02/28](https://doi/10.1056/NEJMoa2002032)
- ``Range = 2.0 - 14.0 days. Mean = 5.6 days (n = 158)`` [20/02/17](https://doi.org/10.3390/jcm9020538)
- ``Range = 2.1 - 11.1 days. Mean = 6.4 days (n = 088)`` [20/02/06](https://doi.org/10.2807/1560-7917.ES.2020.25.5.2000062)
- ``Range = 4.1 - 7.00 days. Mean = 5.2 days (n = 425)`` [20/01/29](https://doi.org/10.1056/NEJMoa2001316)

## Detected presence in Aerosol (airborne transmissibility)
- ``Yes`` [20/03/26](https://doi.org/10.1101/2020.03.23.20039446) (NPR)
- ``Yes (Up to 3 Hours. Half-life = 1.1 hours)`` [20/03/17](https://doi.org/10.1056/NEJMc2004973)
- ``Yes`` [20/03/10](https://doi.org/10.1101/2020.03.08.982637) (NPR)
- ``No`` [20/03/04](https://doi.org/10.1001/jama.2020.3227)

## Viral Shedding
- ``Range = 8 - 37 Days. Median: 20 Days. (n = 137)`` [20/03/11](https://doi.org/10.1016/S0140-6736(20)30566-3)
- ``Range = 12 - 32 Days (n = 4)`` [20/02/27](https://doi.org/10.1001/jama.2020.2783)

## Observed possibility of Reinfection
- ``No (in Macaca mulatta)`` [20/03/14](https://doi.org/10.1101/2020.03.13.990226) (NPR)

## Observed positive test results in patients recovered from COVID-19 after resulting negative
- ``Yes (Stool) `` [20/03/29](https://doi.org/10.1002/jmv.25795)
- ``Yes (RT-PCR)`` [20/03/14](https://doi.org/10.1101/2020.03.13.990226)
- ``Yes (Stool) `` [20/03/14](https://doi.org/10.1053/j.gastro.2020.02.055)

## Case Fatality Rate (CFR) estimates
- ``7.2 % (Italy)``[20/03/23](https://doi:10.1001/jama.2020.4683)
- ``2.3 % (China)``[20/03/23](https://doi:10.1001/jama.2020.4683)
- ``3.4 % (World)``[20/03/19](https://doi.org/10.1016/j.ijantimicag.2020.105947)
- ``1.3 % (OECD countries)``[20/03/19](https://doi.org/10.1016/j.ijantimicag.2020.105947)
- ``13.9 % (of hospitalized patients, World)`` [20/03/13](https://doi.org/10.1016/j.tmaid.2020.101623)
- ``12.2 % (China, Wuhan)``[20/03/13](https://doi.org/10.3201/eid2606.200233)
- ``0.43 % (China excluding Hubei Province)``[20/03/13](https://doi.org/10.3201/eid2606.200233)
- ``Range: 0.25 % – 3.00 % (World)`` [20/03/13](https://doi.org/10.3201/eid2606.200320)
- ``2.3 % (China)``[20/02/29](https://doi.org/10.3855/jidc.12600)
- ``2.3 % (China)``[20/02/24](https://doi.org/10.1001/jama.2020.2648)

## Asymptomatic transmission (now widely recognized in the scientific community)
- ``Yes`` [20/03/19](https://doi.org/10.1056/NEJMc2001737)

## Classification
- ``Superkingdom:`` Viruses
- ``Realm:`` Riboviria
- ``Order:`` Nidovirales
- ``Suborder:`` Cornidovirineae
- ``Family:`` Coronaviridae
- ``Subfamily:`` Orthocoronavirinae
- ``Genus:`` Betacoronavirus
- ``Subgenus:`` Sarbecovirus
- ``Species:`` Severe acute respiratory syndrome-related coronavirus
- ``Strain:``	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
- ``Synonyms:`` HCoV-19, 2019-nCoV, SARS2, COVID-19 virus, Wuhan coronavirus, Human coronavirus 2019

[Lineage Source](https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=2697049)

## Genome
- Size: ``29903 bp`` [20/01/17](https://www.ncbi.nlm.nih.gov/nuccore/MN908947)
- Full sequence: [20/01/17](https://www.ncbi.nlm.nih.gov/nuccore/MN908947.3?report=fasta)

## Potential Seasonal Behavior
- ``No`` [20/03/12](https://dx.doi.org/10.2139/ssrn.3552677)

## Clinical trials of investigational vaccine for COVID-19
- ``ChAdOx1 nCoV-19`` [Start: April 2020 - Estimated Completion: May 2021](https://clinicaltrials.gov/ct2/show/NCT04324606) (Phase 1)
- ``bacTRL-Spike`` [Start: 30 April 2020 - Estimated Completion: 31 December 2021](https://clinicaltrials.gov/ct2/show/NCT04334980) (Phase 1)
- ``BCG`` [Start: 25 March 2020 - Estimated Completion: 25 December 2020](https://clinicaltrials.gov/ct2/show/NCT04328441) (Phase 3)
- ``LV-SMENP`` [Start: 24 March 2020 - Estimated Completion: 31 December 2024](https://clinicaltrials.gov/ct2/show/NCT04276896) (Phase 1 - 2)
- ``Recombinant novel coronavirus vaccine (adenovirus type 5 vector)`` [Start: 16 March 2020 - Estimated Completion: 20 December 2022](https://clinicaltrials.gov/ct2/show/study/NCT04313127) (Phase 1)
- ``mRNA-1273`` [Start: 3 March 2020 - Estimated Completion: 1 June 2021](https://clinicaltrials.gov/ct2/show/NCT04283461) (Phase 1)
- ``aAPC`` [Start: 15 February 2020 - Estimated Completion: 31 December 2024](https://clinicaltrials.gov/ct2/show/NCT04299724)
(Phase 1)

## Examples of clinical trials of investigational drugs for COVID-19
- ``Tocilizumab`` [Start: March 2020 - Estimated Completion: May 2020](https://clinicaltrials.gov/ct2/show/NCT04315480) (Phase 2)
- ``Chloroquine diphosphate`` [Start: 23 March 2020 - Estimated Completion: 31 August 2020](https://clinicaltrials.gov/ct2/show/NCT04323527) (Phase 2)
- ``Colchinine`` [Start: 23 March 2020 - Estimated Completion: September 2020](https://clinicaltrials.gov/ct2/show/NCT04322682) (Phase 3)
- ``Escin`` [Start: 23 March 2020 - Estimated Completion: 30 August 2020](https://clinicaltrials.gov/ct2/show/NCT04322344) (Phase 2)
- ``Methylprednisolone`` [Start: 23 March 2020 - Estimated Completion: 30 May 2020](https://clinicaltrials.gov/ct2/show/NCT04323592) (Phase 2)
- ``Nitric Oxide`` [Start: 21 March 2020 - Estimated Completion: 21 March 2022](https://clinicaltrials.gov/ct2/show/NCT04306393) (Phase 3)
- ``Hydroxychloroquine`` [Start: 17 March 2020 - Estimated Completion: May 2021](https://clinicaltrials.gov/ct2/show/NCT04308668) (Phase 2)
- ``Baricitinib`` [Start: 16 March 2020 - Estimated Completion: 30 April 2021](https://clinicaltrials.gov/ct2/show/NCT04320277) (Phase 3)
- ``Sarilumab`` [Start: 16 March 2020 - Estimated Completion: 16 March 2021](https://clinicaltrials.gov/ct2/show/NCT04315298) (Phase 2)
- ``Remdesivir`` [Start: 10 March 2020](https://clinicaltrials.gov/ct2/show/NCT04302766) (Phase 2)
- ``Favipiravir`` [Start: 8 March 2020 - Estimated Completion: May 2020](https://clinicaltrials.gov/ct2/show/NCT04302766) (Phase 2)
- ``Tetrandrine`` [Start: 5 March 2020 - Estimated Completion: 1 May 2021](https://clinicaltrials.gov/ct2/show/NCT04308317) (Phase 4)
- ``Eculizumab`` [Start: 28 February 2020](https://clinicaltrials.gov/ct2/show/NCT04288713)
- ``Lopinavir/Ritonavir, Ribavirin and Interferon Beta-1B`` [Start: 10 February 2020 - Estimated Completion: 31 July 2022](https://clinicaltrials.gov/ct2/show/NCT04276688) (Phase 2)
- ``Xiyanping`` [Start: 14 February 2020 - Estimated Completion: 14 December 2021](https://clinicaltrials.gov/ct2/show/NCT04275388)
- ``Meplazumab`` [Start: 3 February 2020 - Estimated Completion: 31 December 2020](https://clinicaltrials.gov/ct2/show/NCT04275245) (Phase 1 - 2)
- ``Darunavir and Cobicistat`` [Start: 30 January 2020 - Estimated Completion: 31 December 2020](https://clinicaltrials.gov/ct2/show/NCT04252274) (Phase 3)
- ``Methylprednisolone`` [Start: 26 January 2020 - Estimated Completion: 25 December 2020](https://clinicaltrials.gov/ct2/show/NCT04316377) (Phase 2)
- ``Vitamin C`` [Start: 8 November 2018 - Estimated Completion: 31 December 2022](https://clinicaltrials.gov/ct2/show/NCT04264533) (Phase 3)
